SPECT imaging of the α4β2 nicotinic receptor using [5‐ 123 I]A85380 | Zendy

Pimlott Sally L. | Zendy; Piggott Margaret | Zendy; Patterson James | Zendy; Cavanagh Jonathan | Zendy; Wyper David J. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

SPECT imaging of the α4β2 nicotinic receptor using [5‐ 123 I]A85380

Author(s) -

Pimlott Sally L.,

Piggott Margaret,

Patterson James,

Cavanagh Jonathan,

Wyper David J.

Publication year - 2007

Publication title -

journal of labelled compounds and radiopharmaceuticals

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.432

H-Index - 47

eISSN - 1099-1344

pISSN - 0362-4803

DOI - 10.1002/jlcr.1192

Subject(s) - chemistry , tracer , in vivo , spect imaging , radiochemistry , nuclear medicine , ligand (biochemistry) , nicotinic agonist , medical physics , receptor , biochemistry , nuclear physics , physics , medicine , microbiology and biotechnology , biology

In order to image nAChR density in vivo in humans, [5‐ 123 I]‐iodo‐3‐[2(S)‐2‐azetidinylmethoxy]pyridine ([5‐ 123 I]A85380) has been developed as a SPECT imaging tracer. This article outlines the radiochemical synthesis, in vitro validation in human post‐mortem tissue and some initial in vivo clinical studies using the ligand [5‐ 123/125 I]A85380. Limitations of the usefulness of the tracer for routine clinical use are also discussed. Copyright © 2007 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research